Drug master file (DMF)
•
22 likes•2,252 views
The document discusses the history and current state of the COVID-19 pandemic. It notes that over 4 million cases have been reported worldwide so far in 2020, with the number of cases and deaths continuing to rise in many countries. The author urges readers to take necessary precautions like social distancing and hand washing to help slow the spread of the virus.
Report
Share
Report
Share
Download to read offline
Recommended
Developing clinical trial protocols,institutional review board(irb,iec),infor...
THIS IS THE WRITTEN NOTES ON Developing clinical trial protocols,institutional review board(irb,iec),informed consent ,hippa ,pharmacovigillance safety monitoring in clinical trials, regulation & india scenario.
Generic drugs product development
This is the written note on the topic of generic drug product development.in regulatory affairs subject
Investigation of medicinal product dossier (IMPD)
The document discusses the Investigational Medicinal Product Dossier (IMPD) which contains detailed information on the quality, manufacture, and control of investigational medicinal products tested in clinical trials within the European Union. The IMPD is submitted as part of clinical trial authorization applications to regulatory authorities. It includes summaries of non-clinical and clinical data and a risk-benefit assessment. The IMPD requirements are harmonized across EU member states under regulations established by the European Medicines Agency to facilitate multinational clinical trials.
Pharmacovigilance safety Mon. in clinical trials.pptx
Pharmacovigilance involves monitoring drug safety and adverse effects during clinical trials. Safety monitoring is critical and requires collaboration between stakeholders like sponsors, investigators, ethics committees, and regulators. Common safety monitoring practices include sponsors developing protocols detailing reporting procedures, investigators collecting data in case report forms, and ethics committees and data safety monitoring boards regularly reviewing accumulating trial data to protect participants.
Preformulation concept
This document discusses modern pharmaceutics and preformulation concepts. It begins with an introduction to preformulation, which involves investigating a drug's physical and chemical properties alone and with excipients. This information guides dosage form development. The document then discusses drug-excipient interactions and compatibility testing methods. It also covers topics like solid dispersions, emulsions, suspensions, and parenteral product formulation and testing requirements.
Impd
The document discusses the requirements and contents of an Investigational Medicinal Product Dossier (IMPD) which provides information on the quality, manufacture, and control of investigational medical products (IMPs) used in clinical trials in the European Union. An IMPD includes summaries of nonclinical and clinical data and is required for authorization to perform clinical trials in EU member states. It must provide an overall risk-benefit assessment of the proposed trial based on nonclinical and clinical analyses. A simplified IMPD may be acceptable in some cases such as if the IMP is already authorized. The IMPD covers quality data, nonclinical pharmacology and toxicology data, previous clinical experience, and an overall risk assessment.
Clinical trial protocol development
This document outlines the key components and considerations for developing a clinical trial protocol. It discusses that a protocol is a complete written plan for a research study involving human subjects. It identifies important sections such as the title page, objectives, study design, safety reporting, statistical analysis, and informed consent. It emphasizes that the protocol language should be clear, concise, and understandable for diverse readers. It also provides guidance on properly writing eligibility criteria, adverse event definitions, and obtaining informed consent to protect human subjects.
Regulatory requirement of EU, MHRA & TGA
It involves all regulatory requirements for drug approval or marketing approval in European countries, Australia and UK.
Recommended
Developing clinical trial protocols,institutional review board(irb,iec),infor...
THIS IS THE WRITTEN NOTES ON Developing clinical trial protocols,institutional review board(irb,iec),informed consent ,hippa ,pharmacovigillance safety monitoring in clinical trials, regulation & india scenario.
Generic drugs product development
This is the written note on the topic of generic drug product development.in regulatory affairs subject
Investigation of medicinal product dossier (IMPD)
The document discusses the Investigational Medicinal Product Dossier (IMPD) which contains detailed information on the quality, manufacture, and control of investigational medicinal products tested in clinical trials within the European Union. The IMPD is submitted as part of clinical trial authorization applications to regulatory authorities. It includes summaries of non-clinical and clinical data and a risk-benefit assessment. The IMPD requirements are harmonized across EU member states under regulations established by the European Medicines Agency to facilitate multinational clinical trials.
Pharmacovigilance safety Mon. in clinical trials.pptx
Pharmacovigilance involves monitoring drug safety and adverse effects during clinical trials. Safety monitoring is critical and requires collaboration between stakeholders like sponsors, investigators, ethics committees, and regulators. Common safety monitoring practices include sponsors developing protocols detailing reporting procedures, investigators collecting data in case report forms, and ethics committees and data safety monitoring boards regularly reviewing accumulating trial data to protect participants.
Preformulation concept
This document discusses modern pharmaceutics and preformulation concepts. It begins with an introduction to preformulation, which involves investigating a drug's physical and chemical properties alone and with excipients. This information guides dosage form development. The document then discusses drug-excipient interactions and compatibility testing methods. It also covers topics like solid dispersions, emulsions, suspensions, and parenteral product formulation and testing requirements.
Impd
The document discusses the requirements and contents of an Investigational Medicinal Product Dossier (IMPD) which provides information on the quality, manufacture, and control of investigational medical products (IMPs) used in clinical trials in the European Union. An IMPD includes summaries of nonclinical and clinical data and is required for authorization to perform clinical trials in EU member states. It must provide an overall risk-benefit assessment of the proposed trial based on nonclinical and clinical analyses. A simplified IMPD may be acceptable in some cases such as if the IMP is already authorized. The IMPD covers quality data, nonclinical pharmacology and toxicology data, previous clinical experience, and an overall risk assessment.
Clinical trial protocol development
This document outlines the key components and considerations for developing a clinical trial protocol. It discusses that a protocol is a complete written plan for a research study involving human subjects. It identifies important sections such as the title page, objectives, study design, safety reporting, statistical analysis, and informed consent. It emphasizes that the protocol language should be clear, concise, and understandable for diverse readers. It also provides guidance on properly writing eligibility criteria, adverse event definitions, and obtaining informed consent to protect human subjects.
Regulatory requirement of EU, MHRA & TGA
It involves all regulatory requirements for drug approval or marketing approval in European countries, Australia and UK.
Investigational medical product dossier
Investigational medical product dossier is document made to apply for clinical trial application in European Union. European Medical Agency is regulatory body for drug approval in European Union.
Optimization techniques in pharmaceutical formulation and processing
The document provides an overview of optimization techniques used in pharmaceutical formulation and processing. It begins by defining optimization and its importance in developing drug products that meet bioavailability and mass production requirements. The key parameters of optimization discussed are problem type (constrained vs unconstrained), variables (independent vs dependent), and application areas (formulation vs processing). Several optimization techniques are then outlined, including evolutionary operations, simplex method, Lagrangian method, search method, and canonical analysis. Examples of each technique are provided, such as using simplex to optimize an analytical method or the Lagrangian method to optimize tablet formulation based on two variables.
INDA/NDA/ANDA
Introduction to Investigational new drug application, New drug application, Abbrevated new drug application
Regulatory requirement of EU, MHRA and TGA
The document summarizes regulatory requirements for medicines in the European Union, United Kingdom, Australia, and other countries. The European Medicines Agency regulates medicines for the EU and ensures they are safe, effective and high quality. Medicines must receive market authorization from the EMA or national authorities before sale. The UK's Medicines and Healthcare Products Regulatory Agency regulates clinical trials and product licensing. Australia's Therapeutic Goods Administration ensures medicines available there meet quality, safety and efficacy standards.
ICH & WHO GUIDELINES ON validation
The document provides guidelines on validation of analytical procedures from the International Conference on Harmonisation (ICH) and the World Health Organization (WHO). It discusses validation characteristics like accuracy, precision, specificity, linearity, range, detection limit and quantitation limit that should be considered when validating identification tests, assays, and tests for impurities. It provides definitions for key terms and recommendations on how validation of these characteristics should be performed.
DMF -Drug Master File
DMF is Drug master file which comprises the CMC part(i.e. Chemistry Manufacturing and Critical Control) of the drug substance
MHRA
The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices and blood components for transfusion in the UK. It was formed in 2003 by merging the Medicines Control Agency and Medical Devices Agency. The MHRA licenses pharmaceutical companies, importers, clinical trials and new medicines. It oversees the drug development process from discovery through clinical trials to licensing. The MHRA also monitors drug safety after approval and can renew, cancel or amend licenses as needed.
REGULATIONS FOR COMBINATION PRODUCTS AND MEDICAL DEVICES
This document provides an overview of regulations for combination products and medical devices in the United States and India. It discusses what combination products are, examples of combination products, and the roles of the US FDA Office of Combination Products in classifying and assigning combination products for review. It also summarizes the regulatory requirements for medical devices in the US, including establishment registration, medical device listing, premarket notification, premarket approval, and quality system regulations. The latest developments in medical device regulation in India are also briefly outlined.
Generic drug product development
- Generic drugs are comparable to brand name drugs in dosage, quality, and intended use but are cheaper. They contain the same active ingredients as original formulations.
- The generic drug development process involves concept development, system-level design, detail design, testing and refinement, production ramp-up, and product launch. It aims to develop affordable drugs that balance public health needs.
- Generic drugs are available after patents or marketing rights expire on brand name drugs. They maintain quality at affordable prices for critical diseases.
Drug master file
A topic from QCQA which is documentary work for pharmaceutical drug substance and drug products. This DMF is files as per the USFDA guidelines .
Anda
This document summarizes the regulations and history around generic drug applications (ANDAs) in the United States. It explains that an ANDA is an application to produce a generic version of an approved drug that is the same in dosage, strength, and use. The document outlines the basic requirements for generic drugs and discusses the historical approval pathways including ANDAs, paper NDAs, and monographs that preceded the modern system established by the Hatch-Waxman Act of 1984. This law standardized the ANDA process and established provisions to balance generic competition with patent protections for brand drugs.
Validation and calibration of master plan
This document outlines validation and calibration master plans. It discusses the objectives of validation including reducing risks and costs. It describes the contents and members involved in a validation master plan, which provides the framework for validation activities. It also discusses the calibration process, including defining calibrated equipment, classification, and verification. The calibration master plan establishes requirements for an effective calibration control program.
Validation and calibration master plan
This document provides an overview of pharmaceutical validation and calibration processes. It discusses the objectives of validation which include reducing regulatory risks and defects. The scope of validation covers analytical, facilities, manufacturing, product design, cleaning, instrumentation, utilities, materials and equipment. A validation master plan outlines the validation strategy and includes qualification methods, personnel responsibilities, schedules, documentation and change control. Similarly, a calibration master plan ensures equipment is routinely calibrated against reference standards to ensure proper performance and measurement traceability.
Drug excipient interaction different method
This document discusses excipients and their role in drug formulations. It notes that excipients are ingredients other than the active pharmaceutical ingredient that are used to formulate dosage forms. Excipients can act as protective agents, bulking agents, and can improve drug bioavailability. The document then lists common types of excipients and potential interactions between drugs and excipients, such as physical, chemical, biopharmaceutical, and excipient-excipient interactions. It describes several analytical techniques used to detect drug-excipient interactions, including DSC, accelerated stability studies, FT-IR, DRS, chromatography methods, and others.
cmc [ chemistry manufacturing control ]
This document provides information about Chemistry, Manufacturing and Controls (CMC) regulatory affairs. It discusses the responsibilities of CMC regulatory affairs in providing leadership, strategy and regulatory knowledge to achieve approval of pharmaceutical products. It also summarizes key elements included in CMC regulatory submissions like manufacturing sites, analytical methods and quality testing data. The document further discusses post-approval regulatory requirements including post-approval studies and safety surveillance. It provides examples of combination products and medical device regulations. It introduces the Common Technical Document (CTD) format for registration applications and its electronic version (eCTD). Finally, it summarizes some key ICH guidelines.
Clinical trials First Year M. Pharmacy.
The document discusses three topics:
1) Institutional Review Boards, which protect the rights and welfare of clinical trial subjects. IRBs review and approve research protocols.
2) HIPAA, which establishes standards to protect private health information. It covers entities like health plans and providers.
3) Pharmacovigilance, which monitors the safety of medicines. It aims to identify new hazards and improve patient outcomes. Adverse drug reactions and side effects are reported to monitoring programs.
Quality by Design ( QbD )
Quality by Design is pharmaceutical product development which ensures the product quality, ICH Guideline Q8 is provide the guidelines about QbD.
Global Subbmission of IND, NDA, ANDA
Regulatory approval of NDA, ANDA, and IND
Guided by
Dr.Yogannada R
Professor and Head
Dept of Pharmacy Practice
SJM College of Pharamcy
Chotardurga
Cmc, post approval and regulation
Details on regulatory affairs for pharmaceutical sector, Regulation of medical device and combination product
Regulatory requirements for API and Biologics
The document discusses regulatory requirements for active pharmaceutical ingredients (APIs) and biologics. It provides an overview of regulatory guidelines for APIs, including requirements for registration of APIs with agencies like the FDA. It also describes regulatory filings like Drug Master Files (DMFs) that are submitted to provide confidential manufacturing information to support applications. Requirements for biologics are also briefly covered, noting they are complex molecules produced through biotechnology.
Human Nervous system
The nervous system is divided into the central nervous system (brain and spinal cord) and peripheral nervous system. It coordinates the body's activities and transmits signals via neurons, which are composed of a cell body, dendrites, and an axon. Neuroglia provide support and protection to the neurons. The nervous system consists of sensory neurons that receive information, interneurons that communicate within the central nervous system, and motor neurons that activate muscles and glands. A nerve impulse is transmitted through neurons via changes in electrical charges across the cell membrane.
Somatic & special senses
The document provides information on the somatic and special senses. It discusses the different types of receptors including chemoreceptors, nociceptors, thermoreceptors, mechanoreceptors, and photoreceptors. It then describes the specific senses - touch, pain, temperature, taste, smell, hearing, equilibrium, sight. For each sense, it outlines the receptors involved, their location, and how sensory information is transmitted to the brain. The document also reviews the anatomy and physiology associated with smell, hearing, taste, equilibrium, and vision.
More Related Content
What's hot
Investigational medical product dossier
Investigational medical product dossier is document made to apply for clinical trial application in European Union. European Medical Agency is regulatory body for drug approval in European Union.
Optimization techniques in pharmaceutical formulation and processing
The document provides an overview of optimization techniques used in pharmaceutical formulation and processing. It begins by defining optimization and its importance in developing drug products that meet bioavailability and mass production requirements. The key parameters of optimization discussed are problem type (constrained vs unconstrained), variables (independent vs dependent), and application areas (formulation vs processing). Several optimization techniques are then outlined, including evolutionary operations, simplex method, Lagrangian method, search method, and canonical analysis. Examples of each technique are provided, such as using simplex to optimize an analytical method or the Lagrangian method to optimize tablet formulation based on two variables.
INDA/NDA/ANDA
Introduction to Investigational new drug application, New drug application, Abbrevated new drug application
Regulatory requirement of EU, MHRA and TGA
The document summarizes regulatory requirements for medicines in the European Union, United Kingdom, Australia, and other countries. The European Medicines Agency regulates medicines for the EU and ensures they are safe, effective and high quality. Medicines must receive market authorization from the EMA or national authorities before sale. The UK's Medicines and Healthcare Products Regulatory Agency regulates clinical trials and product licensing. Australia's Therapeutic Goods Administration ensures medicines available there meet quality, safety and efficacy standards.
ICH & WHO GUIDELINES ON validation
The document provides guidelines on validation of analytical procedures from the International Conference on Harmonisation (ICH) and the World Health Organization (WHO). It discusses validation characteristics like accuracy, precision, specificity, linearity, range, detection limit and quantitation limit that should be considered when validating identification tests, assays, and tests for impurities. It provides definitions for key terms and recommendations on how validation of these characteristics should be performed.
DMF -Drug Master File
DMF is Drug master file which comprises the CMC part(i.e. Chemistry Manufacturing and Critical Control) of the drug substance
MHRA
The Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicines, medical devices and blood components for transfusion in the UK. It was formed in 2003 by merging the Medicines Control Agency and Medical Devices Agency. The MHRA licenses pharmaceutical companies, importers, clinical trials and new medicines. It oversees the drug development process from discovery through clinical trials to licensing. The MHRA also monitors drug safety after approval and can renew, cancel or amend licenses as needed.
REGULATIONS FOR COMBINATION PRODUCTS AND MEDICAL DEVICES
This document provides an overview of regulations for combination products and medical devices in the United States and India. It discusses what combination products are, examples of combination products, and the roles of the US FDA Office of Combination Products in classifying and assigning combination products for review. It also summarizes the regulatory requirements for medical devices in the US, including establishment registration, medical device listing, premarket notification, premarket approval, and quality system regulations. The latest developments in medical device regulation in India are also briefly outlined.
Generic drug product development
- Generic drugs are comparable to brand name drugs in dosage, quality, and intended use but are cheaper. They contain the same active ingredients as original formulations.
- The generic drug development process involves concept development, system-level design, detail design, testing and refinement, production ramp-up, and product launch. It aims to develop affordable drugs that balance public health needs.
- Generic drugs are available after patents or marketing rights expire on brand name drugs. They maintain quality at affordable prices for critical diseases.
Drug master file
A topic from QCQA which is documentary work for pharmaceutical drug substance and drug products. This DMF is files as per the USFDA guidelines .
Anda
This document summarizes the regulations and history around generic drug applications (ANDAs) in the United States. It explains that an ANDA is an application to produce a generic version of an approved drug that is the same in dosage, strength, and use. The document outlines the basic requirements for generic drugs and discusses the historical approval pathways including ANDAs, paper NDAs, and monographs that preceded the modern system established by the Hatch-Waxman Act of 1984. This law standardized the ANDA process and established provisions to balance generic competition with patent protections for brand drugs.
Validation and calibration of master plan
This document outlines validation and calibration master plans. It discusses the objectives of validation including reducing risks and costs. It describes the contents and members involved in a validation master plan, which provides the framework for validation activities. It also discusses the calibration process, including defining calibrated equipment, classification, and verification. The calibration master plan establishes requirements for an effective calibration control program.
Validation and calibration master plan
This document provides an overview of pharmaceutical validation and calibration processes. It discusses the objectives of validation which include reducing regulatory risks and defects. The scope of validation covers analytical, facilities, manufacturing, product design, cleaning, instrumentation, utilities, materials and equipment. A validation master plan outlines the validation strategy and includes qualification methods, personnel responsibilities, schedules, documentation and change control. Similarly, a calibration master plan ensures equipment is routinely calibrated against reference standards to ensure proper performance and measurement traceability.
Drug excipient interaction different method
This document discusses excipients and their role in drug formulations. It notes that excipients are ingredients other than the active pharmaceutical ingredient that are used to formulate dosage forms. Excipients can act as protective agents, bulking agents, and can improve drug bioavailability. The document then lists common types of excipients and potential interactions between drugs and excipients, such as physical, chemical, biopharmaceutical, and excipient-excipient interactions. It describes several analytical techniques used to detect drug-excipient interactions, including DSC, accelerated stability studies, FT-IR, DRS, chromatography methods, and others.
cmc [ chemistry manufacturing control ]
This document provides information about Chemistry, Manufacturing and Controls (CMC) regulatory affairs. It discusses the responsibilities of CMC regulatory affairs in providing leadership, strategy and regulatory knowledge to achieve approval of pharmaceutical products. It also summarizes key elements included in CMC regulatory submissions like manufacturing sites, analytical methods and quality testing data. The document further discusses post-approval regulatory requirements including post-approval studies and safety surveillance. It provides examples of combination products and medical device regulations. It introduces the Common Technical Document (CTD) format for registration applications and its electronic version (eCTD). Finally, it summarizes some key ICH guidelines.
Clinical trials First Year M. Pharmacy.
The document discusses three topics:
1) Institutional Review Boards, which protect the rights and welfare of clinical trial subjects. IRBs review and approve research protocols.
2) HIPAA, which establishes standards to protect private health information. It covers entities like health plans and providers.
3) Pharmacovigilance, which monitors the safety of medicines. It aims to identify new hazards and improve patient outcomes. Adverse drug reactions and side effects are reported to monitoring programs.
Quality by Design ( QbD )
Quality by Design is pharmaceutical product development which ensures the product quality, ICH Guideline Q8 is provide the guidelines about QbD.
Global Subbmission of IND, NDA, ANDA
Regulatory approval of NDA, ANDA, and IND
Guided by
Dr.Yogannada R
Professor and Head
Dept of Pharmacy Practice
SJM College of Pharamcy
Chotardurga
Cmc, post approval and regulation
Details on regulatory affairs for pharmaceutical sector, Regulation of medical device and combination product
Regulatory requirements for API and Biologics
The document discusses regulatory requirements for active pharmaceutical ingredients (APIs) and biologics. It provides an overview of regulatory guidelines for APIs, including requirements for registration of APIs with agencies like the FDA. It also describes regulatory filings like Drug Master Files (DMFs) that are submitted to provide confidential manufacturing information to support applications. Requirements for biologics are also briefly covered, noting they are complex molecules produced through biotechnology.
What's hot (20)
Optimization techniques in pharmaceutical formulation and processing
Optimization techniques in pharmaceutical formulation and processing
REGULATIONS FOR COMBINATION PRODUCTS AND MEDICAL DEVICES
REGULATIONS FOR COMBINATION PRODUCTS AND MEDICAL DEVICES
More from Bashant Kumar sah
Human Nervous system
The nervous system is divided into the central nervous system (brain and spinal cord) and peripheral nervous system. It coordinates the body's activities and transmits signals via neurons, which are composed of a cell body, dendrites, and an axon. Neuroglia provide support and protection to the neurons. The nervous system consists of sensory neurons that receive information, interneurons that communicate within the central nervous system, and motor neurons that activate muscles and glands. A nerve impulse is transmitted through neurons via changes in electrical charges across the cell membrane.
Somatic & special senses
The document provides information on the somatic and special senses. It discusses the different types of receptors including chemoreceptors, nociceptors, thermoreceptors, mechanoreceptors, and photoreceptors. It then describes the specific senses - touch, pain, temperature, taste, smell, hearing, equilibrium, sight. For each sense, it outlines the receptors involved, their location, and how sensory information is transmitted to the brain. The document also reviews the anatomy and physiology associated with smell, hearing, taste, equilibrium, and vision.
The skin & integumentary system. ppt
The skin & integumentary system is based on the CTEVT syllabus for diploma in health sciences, Anatomy, and physiology,
Novel drug delivery system
Novel drug delivery system, nanoparticles, resealed erythrocytes, niosomes, microspheres. It also contains information about virus, bacterias and their removal methods and sterility methods.
Nepal Pharmacy Council Model Questions with Answer keys
MCQS, most probable questions compiled from the GPAT old exam questions, old council and LokSewa questions, pharmacology, jurisprudence, pharmaceutics, pharmacognosy, chemistry, hospital pharmacy.
Drug Discovery, Development and Commercialization
its not my personal work presentation but taken from lecture ppt from university of San Diego, california.
Its about the drug discovery process, its development and its commercialization.
Scientific writing Tips and Ideas
it is about ideas and tips on how to write scientific writings like review, research articles papers as well as grants writing. its the preliminary things to know before the start to publish article.
Formulation and evaluation of folding film in a capsule for gastroretentive d...
This document describes research into developing a gastroretentive drug delivery system for losartan potassium using folding films enclosed in capsules. Sustained release films were prepared using polymers like HPMC and ethyl cellulose with polyethylene glycol as a plasticizer, through a solvent casting method. The films were evaluated for parameters like weight variation, thickness, folding endurance, tensile strength, drug content uniformity, surface pH and dissolution. A 2^3 factorial design was used to optimize the formulations, evaluating the effects of polymer amount, plasticizer amount, and coating solution concentration on drug release. The optimized formulations showed sustained drug release and remained stable over 30 days in accelerated stability studies.
Quality by design in pharmaceutical development
This document outlines the key details of a home sale located at 123 Main St from the seller John Doe to the buyer Jane Smith. The three bedroom, two bathroom home was sold for $250,000 with the transaction closing on May 15th, 2022. John and Jane both signed the contract agreeing to the terms of the sale for the property located at 123 Main St.
Optimization methodologies
This document outlines the terms and conditions for a home loan agreement between a lender and borrower. It details the loan amount, interest rate, repayment schedule, late fees, prepayment rules, default conditions, and foreclosure process if the borrower fails to meet the obligations of the loan. The lender and borrower must sign and date the document to finalize the agreement.
History of computers in research and development
its the written notes on the topic History of computers in research and development usefiul for the CADD subject
Computational modelling of drug disposition
its the written notes on the topic Computational modelling of drug disposition use ful for the 2nd mpharm students
Biowavier consideration, fed vs fasted state, psa , computer simulation in ph...
its written notes on the topic "Biowavier consideration, fed vs fasted state, psa , computer simulation in pharmacokinetics"
Compression and compaction
This document outlines the terms and conditions for a rental agreement between John Doe and Jane Smith for the property located at 123 Main St. It specifies the monthly rental rate of $1,000 due on the 1st of each month, the security deposit of $500, allows for pets with an additional $100 fee, and holds both parties accountable for repairs and damages that may occur during the lease period.
Current goods manufacturing practice
This document outlines the terms and conditions for a rental agreement between John Doe and Jane Smith for the lease of an apartment located at 123 Main St from January 1, 2023 through December 31, 2023. Key details include the monthly rent amount, late fees, repairs and maintenance responsibilities, entry rules, and terms for lease renewal or termination.
Validation and validation of master plan in modern pharmaceutics.
this is the written note on validation topic in the modern pharmaceutics subject of mpharm 1st semester.
MFR (master formula record )
The document discusses a proposed settlement agreement between two parties, John Doe and Richard Roe, to resolve a legal dispute over an automobile accident. The agreement states that John Doe will pay Richard Roe $5,000 in damages and that both parties will dismiss all claims against each other to avoid further legal proceedings. In exchange for the payment and dismissal of claims, Richard Roe agrees to release John Doe from any liability related to the accident.
Scale up process approval changes post-marketing survelliance- outsourcing B...
This is the note on Scale up process approval changes post-marketing survelliance- outsourcing BA & BE to CRO
X ray production, x- ray diffraction, bragg's law, & application
this is the hand written notes on X ray production, x- ray diffraction, bragg's law, & application for 1st semester mpharm
NMR spectroscopy
this is the note on NMR spectrometry which contains coupling and spliting along with its application.
More from Bashant Kumar sah (20)
Nepal Pharmacy Council Model Questions with Answer keys
Nepal Pharmacy Council Model Questions with Answer keys
Formulation and evaluation of folding film in a capsule for gastroretentive d...
Formulation and evaluation of folding film in a capsule for gastroretentive d...
Biowavier consideration, fed vs fasted state, psa , computer simulation in ph...
Biowavier consideration, fed vs fasted state, psa , computer simulation in ph...
Validation and validation of master plan in modern pharmaceutics.
Validation and validation of master plan in modern pharmaceutics.
Scale up process approval changes post-marketing survelliance- outsourcing B...
Scale up process approval changes post-marketing survelliance- outsourcing B...
X ray production, x- ray diffraction, bragg's law, & application
X ray production, x- ray diffraction, bragg's law, & application
Recently uploaded
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...chandankumarsmartiso
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun Women Seeking Service
Light House Retreats: Plant Medicine Retreat Europe
Our aim is to organise conscious gatherings and retreats for open and inquisitive minds and souls, with and without the assistance of sacred plants.
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
A Classical Text Review on Basavarajeeyam
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptxMGM SCHOOL/COLLEGE OF NURSING
Identification and nursing management of congenital malformations REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
It includes regulation of combination products and medical devices. FDA and industry liaisons.
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
PPT RELATED TO ARTHROLOGY ACCORDING TO NCISM AYURVEDA
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Physiology of Special Chemical Sensation of Taste
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
micro teaching on communication m.sc nursing.pdf
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Recently uploaded (20)
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
#cALL# #gIRLS# In Dehradun ꧁❤8107221448❤꧂#cALL# #gIRLS# Service In Dehradun W...
Light House Retreats: Plant Medicine Retreat Europe
Light House Retreats: Plant Medicine Retreat Europe
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Basavarajeeyam - Ayurvedic heritage book of Andhra pradesh
Identification and nursing management of congenital malformations .pptx
Identification and nursing management of congenital malformations .pptx
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Integrating Ayurveda into Parkinson’s Management: A Holistic Approach
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Ear and its clinical correlations By Dr. Rabia Inam Gandapore.pptx
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...